• BrainStorm Cell Therapeutics Inc., of New York, said it priced a registered public offering. It agreed to sell to investors about 19.8 million shares of common stock priced at 29 cents per share, representing gross proceeds of about $5.75 million. Investors also will receive warrants for about 14.9 million shares. Net proceeds will total about $4.78 million and will be used to fund clinical trials in the U.S. and Israel, R&D, working capital needs, capital expenditures and other general corporate purposes. BrainStorm develops adult stem cell products, derived from autologous bone marrow cells, for the treatment of neurodegenerative diseases. Its lead program is in Phase I/II trials in amyotrophic lateral sclerosis. Maxim Group LLC served as lead placement agent for the offering. Shares of BrainStorm (OTCBB:BCLI) closed Tuesday at 26 cents, down 3 cents.

• Domain Therapeutics SA, of Strasbourg, France, completed a financing round worth €2 million (US$2.4 million) from new investors Seventure Partners and SODIV, and previous investors AIRFI, IP Growth, Auriga and Domain board chairman Sam Eletr. The financing will support the company's implementation of a new business strategy of transitioning from contract research to collaborations and strategic alliances.

• Fibrocell Science Inc., of Exton, Pa., completed a private placement of preferred stock and warrants for $9. 1 million. The placement was originally commenced in May, and John Carris Investments LLC and John Thomas Financial Inc. acted as co-placement agents for the transaction. Fibrocell markets Laviv (azficel-T), a cell therapy for nasolabial fold wrinkles.